Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2010-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective / hypothesis The study aims to (1) measure the prevalence of psychotic symptoms in the Hong Kong population; (2) explore associated risk and protective factors for the expression of psychotic symptoms; (3) characterize the functional disability in people with psychotic symptoms; and (4) study the determinant of clinical presentation or non-presentation in people with psychotic symptoms.
Design, subjects and study instrument The survey will be conducted with a two-phase design. The first phase interviews will include approximately 5,000 subjects with structured assessments serving diagnostic criteria for CMD, screening instruments for psychotic disorder, substance misuse and suicidal behaviours, functioning, service use and demographics. The second phase comprises of clinician interviews for psychotic disorder and "at risk mental state" and other variables including neurocognitive, help seeking, stigma and well-being.
Analysis Prevalence estimates will be weighted, expressed as rates and confidence intervals. Comorbidity will be estimated using Latent Class Analysis (LCA) Logistic regression will be used to identify significant factors associated with mental disorders.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stage-specific Case Management for Early Psychosis
NCT00919620
Optimal Duration of Early Intervention for Psychosis
NCT01202357
Mental Health During the Whole Life Cycle of Community Patients with Schizophrenia
NCT05159349
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
NCT00654576
Early Medication Discontinuation and Long-term Clinical Outcome in FEP
NCT01926340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Availability data suggest that the prevalence of psychosis in the community is substantially higher (5.5-28%, vanos 09) than the prevalence of treated disorder (1-3.5%, vanos09 ), raising important questions about the what determines whether and when psychotic disorders are intercepted in a particular service setting. It is vital to also to obtain information about the untreated cases, in terms of risk factors and protective factors, disability, as well as obstacles to help-seeking.
Community level data for psychotic disorders in Hong Kong is sparse and there has been no territory-wide population-level epidemiology. The Hong Kong population has several distinctive features which are of particular scientific interest and public health concern in relation to psychosis. Although the overall prevalence of substance abuse is low, there is disproportionate use of ketamine in Hong Kong, which interferes with glutaminergic neurotransmission. The relationship between ketamine use and risk for psychosis is of aetiological and clinical interest. In addition, the unique societal context of Hong Kong has resulted in a high proportion of immigrants from China. Moreover, a cohort of people with relatively high paternal age is entering the risk period of developing psychotic disorders (resulting from older man from Hong Kong and younger women from neighbouring parts of China in the previous decades).
Previous relevant study included a district survey, which was more than a quarter of a century old, and was of limited generalization value because of the uneven socioeconomic distribution amongst Hong Kong's 18 districts, resulting in likely uneven distribution of individual with psychosis amongst them. Other relevant data included data of treated new onset cases from Hong Kong's early intervention service (EASY, annual incidence of at least 600 cases under 25, and estimated 1200-1500 in all age groups), with the limitations of treated incidence discussed above.
The investigators propose a territory-wide epidemiological study of psychosis. The study aims to (1) measure the prevalence of psychotic symptoms in the Hong Kong population; (2) explore associated risk and protective factors for the expression of psychotic symptoms; (3) characterize the functional disability in people with psychotic symptoms; and (4) study the determinant of clinical presentation or non-presentation in people with psychotic symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Community dwelling adult population
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The sample for this survey is planned to represent community dwelling adult population in Hong Kong. The age range will be from 16-75 years. People residing in institutions will not be covered. Only Chinese subjects will be recruited. The survey will adopt a multi-stage sampling design. The sampling frame will consist of a random selection of addresses quarters generated with the help of the Censes and Statistics Department of the Government of Hong Kong SAR. The addresses would be stratified with geographical location and nature of premises. For each address identified, an advance letter with return envelop or contact information will be sent. The advance letter will inform the residents about the nature of the study with an invitation for participation. A maximum of five invitations will be sent by post for non-return within three months. A trained lay interviewer will conduct Phase 1 assessment at home visit for each eligible household expressing interest to participate. To avoid inflation of characteristics that may aggregate within families, only one adult aged 16 years or over will be selected randomly for interview in each household.
Exclusion Criteria
16 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen Mary Hospital, Hong Kong
OTHER
Kowloon Hospital, Hong Kong
OTHER
Castle Peak Hospital
OTHER_GOV
North District Hospital, Hong Kong
UNKNOWN
Shatin Hospital
OTHER
Tai Po Hospital
OTHER_GOV
Kwai Chung Hospital
OTHER
Prince of Wales Hospital, Shatin, Hong Kong
OTHER
The University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
The University of Hong Kong
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
May Mei-ling LAM, MBBS
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Hong Kong
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
May Mei-ling Lam, MBBS
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Epi-2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.